175 related articles for article (PubMed ID: 26588333)
21. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
22. Consumption of the epidermis in acral lentiginous melanoma.
Ohata C; Nakai C; Kasugai T; Katayama I
J Cutan Pathol; 2012 Jun; 39(6):577-81. PubMed ID: 22574622
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
24. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
25. Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling.
Paluncic J; Kovacevic Z; Jansson PJ; Kalinowski D; Merlot AM; Huang ML; Lok HC; Sahni S; Lane DJ; Richardson DR
Biochim Biophys Acta; 2016 Apr; 1863(4):770-84. PubMed ID: 26844774
[TBL] [Abstract][Full Text] [Related]
26. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
27. Biological behavior and natural course of acral malignant melanoma. Clinical and histologic features and prognosis of palmoplantar, subungual, and other acral malignant melanomas.
Jimbow K; Takahashi H; Miura S; Ikeda S; Kukita A
Am J Dermatopathol; 1984; 6 Suppl():43-53. PubMed ID: 6528942
[TBL] [Abstract][Full Text] [Related]
28. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
Niu HT; Zhou QM; Wang F; Shao Q; Guan YX; Wen XZ; Chen LZ; Feng QS; Li W; Zeng YX; Zhang XS
Pigment Cell Melanoma Res; 2013 Sep; 26(5):646-53. PubMed ID: 23751074
[TBL] [Abstract][Full Text] [Related]
29. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
30. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Ashida A; Takata M; Murata H; Kido K; Saida T
Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
[TBL] [Abstract][Full Text] [Related]
31. Significance of vascular endothelial growth factor expression in skin melanoma.
Gajanin V; Krivokuća Z; Kostić K; Gajanin R; Sladojević I
Vojnosanit Pregl; 2010 Sep; 67(9):747-54. PubMed ID: 20949875
[TBL] [Abstract][Full Text] [Related]
32. Association of galectin-3 expression with melanoma progression and prognosis.
Brown ER; Doig T; Anderson N; Brenn T; Doherty V; Xu Y; Bartlett JM; Smyth JF; Melton DW
Eur J Cancer; 2012 Apr; 48(6):865-74. PubMed ID: 22071132
[TBL] [Abstract][Full Text] [Related]
33. [Acral-lentiginous melanoma: the newest subgroup of malignant melanomas of the skin].
Panizzon R; Stieger M; Schüler G; Hardmeier T
Schweiz Med Wochenschr; 1982 Apr; 112(17):612-8. PubMed ID: 7089511
[TBL] [Abstract][Full Text] [Related]
34. TERT and AURKA gene copy number gains enhance the detection of acral lentiginous melanomas by fluorescence in situ hybridization.
Diaz A; Puig-Butillé JA; Valera A; Muñoz C; Costa D; Garcia-Herrera A; Carrera C; Sole F; Malvehy J; Puig S; Alos L
J Mol Diagn; 2014 Mar; 16(2):198-206. PubMed ID: 24374110
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.
Lang J; MacKie RM
J Invest Dermatol; 2005 Sep; 125(3):575-9. PubMed ID: 16117801
[TBL] [Abstract][Full Text] [Related]
36. Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.
Busam KJ; Vilain RE; Lum T; Busam JA; Hollmann TJ; Saw RP; Coit DC; Scolyer RA; Wiesner T
Am J Surg Pathol; 2016 Jun; 40(6):786-95. PubMed ID: 26872010
[TBL] [Abstract][Full Text] [Related]
37. Distinctive dermatoscopic features of acral lentiginous melanoma in situ from plantar melanocytic nevi and their histopathologic correlation.
Kawabata Y; Tamaki K
J Cutan Med Surg; 1998 Apr; 2(4):199-204. PubMed ID: 9558302
[TBL] [Abstract][Full Text] [Related]
38. Acral lentiginous melanoma.
Piliang MP
Clin Lab Med; 2011 Jun; 31(2):281-8. PubMed ID: 21549241
[TBL] [Abstract][Full Text] [Related]
39. Expression of p16 protein in acral lentiginous melanoma.
Hsieh R; Firmiano A; Sotto MN
Int J Dermatol; 2009 Dec; 48(12):1303-7. PubMed ID: 20415670
[TBL] [Abstract][Full Text] [Related]
40. Novel inhibitors in the treatment of metastatic melanoma.
Kalinsky K; Haluska FG
Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
